NEW YORK–(BUSINESS WIRE)–Avoro Ventures, a global venture capital firm investing in life sciences, announced the final close of its inaugural fund, Avoro Ventures Fund L.P. (“The Fund”), with $186 million in total of capital commitments.

The launch of Avoro Ventures serves as an extension to the established life sciences business at Avoro Capital, creating a distinct, complimentary portfolio of private market investments. The Fund has completed three investments and will continue to pursue development-stage biotechnology opportunities to help deliver breakthrough therapies to patients.

In addition to the close of the Fund, Avoro Ventures is also pleased to announce the appointment of Uya Chuluunbaatar, PhD., as a Partner focusing on the firm’s venture capital investment efforts. Dr. Chuluunbaatar joins Avoro Ventures with over 15 years’ experience in healthcare across a range of functions including venture capital, public equity investing, technology transfer and academic research. Prior to Avoro Ventures she was a Principal at Amzak Health where she oversaw 13 venture investments, resulting in 7 exits.

Dr. Chuluunbaatar will join Behzad Aghazadeh, PhD, Managing Partner of Avoro Ventures, Garheng Kong, MD/PhD, Avoro Ventures Advisory Partner, and the Avoro Ventures team.

About Avoro Ventures

Avoro Ventures is an affiliated company of Avoro Capital Advisors, an SEC-registered investment manager based in New York City primarily focused on life sciences and biotechnology.

Contacts

Andy Merrill
Prosek Partners
amerrill@prosek.com